Patient Guide: MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (AR

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • ✓ Get matched to the right study location for you
  • ✓ Connect directly with study coordinators at 1 participating sites
  • ✓ Understand eligibility with our simplified screening tool
  • ✓ Free service - we're here to help you access clinical research
Trial ID: NCTNCT05536752
Status: COMPLETED_NEXT_PHASE_UPCOMING
Condition: intermediate dry age-related macular degeneration, intermediate atrophic AMD
Phase: PHASE2

Find a Study Location Near You

This study is available at 1 research site. We'll help you connect with the location that's right for you.

Participating sites include:
  • • ,

Loading interactive enrollment tools...

The full interactive experience will load momentarily

MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (AR - Join Clinical Trial NCTNCT05536752

How to Join This Clinical Trial - NCTNCT05536752

Learn how to participate in this PHASE2 trial studying QA102 for intermediate dry age-related macular degeneration, intermediate atrophic AMD. Current status: COMPLETED_NEXT_PHASE_UPCOMING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with intermediate dry age-related macular degeneration, intermediate atrophic AMD. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
intermediate dry age-related macular degeneration, intermediate atrophic AMD
Treatment Being Tested
QA102
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
COMPLETED_NEXT_PHASE_UPCOMING
Study Identifier
NCTNCT05536752 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 1 locations. Find a study site near you:

Clinical Research Site

, - China

Status: Contact for availability

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for intermediate dry age-related macular degeneration, intermediate atrophic AMD:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai as Your Clinical Trial Matching Service

Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:

  • Find clinical trials that match your condition
  • Get matched to the right study location near you
  • Connect directly with study coordinators
  • Understand if you qualify with simplified eligibility screening
  • Navigate the enrollment process with personalized support
  • Access new treatments through clinical research participation